SGLT2i may be underprescribed in Blacks (and non-Blacks). Medicare FFS claims between 2012 and 2018 showed Black CKD patients with diabetes were less likely than non-Blacks (10.2 vs. 14.2%) to have started using SGLT2i and glucagon-like peptide 1 receptor agonists (GLP-1RA), another newer glucose-lowering medication with demonstrated cardiovascular and kidney protective benefits [217,218]. Analysis of the Optum Clinformatics Data Mart showed 17% lower odds of SGLT2i use in Black than White CKD patients [219]. The gene discussed is GLP1R; the disease is chronic kidney disease.